Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank

Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank J McLauchlan, H Innes,* JF Dillon, G Foster, E Holtham, S McDonald, B Wilkes, SJ Hutchinson and WL Irving on behalf of the HCV Research UK Steering Committee MRC-University of Glasgow Centre for Virus Research, Glasgow, UK, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK, Blood Borne Viruses and STIs Division, Health Protection Scotland, Glasgow, UK, Division of Molecular and Clinical Medicine; University of Dundee, Dundee, UK, Institute of Cell and Molecular Science, Queen Mary University of London, London, UK and National Institute for Health Research (NIHR) Digestive Diseases Biomedical Research Unit at Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK

[1]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[2]  P. Cacoub,et al.  Chronic hepatitis C virus infection, a new cardiovascular risk factor? , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[3]  Ding‐Shinn Chen,et al.  Hepatitis C viral infection increases the risk of lymphoid‐neoplasms: A population‐based cohort study , 2016, Hepatology.

[4]  N. Hawkes.  NICE approval of new hepatitis drug could result in £700m bill for NHS , 2015, BMJ : British Medical Journal.

[5]  J. Lewsey,et al.  Predictors of admission and readmission to hospital for major depression: A community cohort study of 52,990 individuals. , 2015, Journal of affective disorders.

[6]  P. Cacoub,et al.  Extrahepatic manifestations of chronic hepatitis C virus infection , 2016, Therapeutic advances in infectious disease.

[7]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[8]  T. Liang,et al.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis , 2013, Hepatology.

[9]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[10]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[11]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[12]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[13]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[14]  T. Asselah,et al.  Fibrosis and disease progression in hepatitis C , 2002, Hepatology.